Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S J Waters

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
The Journal of Experimental Medicine|January 1, 1984
Antigen recognition by a T cell clone outside the context of the major histocompatibility complex. A role for Mls in antigen presentationS J Waters, S D Waksal, G P Norton, et al.
Investigational New Drugs|September 20, 2001
Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulvenA L Woynarowska BAHigdon, R M Muñoz, P Bushong, et al.
The American Review of Respiratory Disease|May 1, 1983
Immunogenetic and clinical findings in idiopathic pulmonary fibrosis. Association with the B-cell alloantigen HLA-DR2D M Libby, A Gibofsky, M Fotino, et al.
Journal of Pharmaceutical Sciences|September 1, 1995
Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparisonP Veng-Pedersen, J A Wilhelm, T B Zakszewski, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1984
Antigen presentation by murine and human cells to a murine T-cell hybridoma: demonstration of a restriction element associated with a major histocompatibility complex class II determinant(s) shared by both speciesS J Waters, R J Winchester, F Nagase, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 1, 1995
Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimationJ A Wilhelm, P Veng-Pedersen, T B Zakszewski, et al.
Anesthesia and Analgesia|August 1, 1986
Oxygen concentrations required for reductive defluorination of halothane by rat hepatic microsomesR C Lind, A J Gandolfi, I G Sipes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2004
Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenograftsE S van Laar, E Izbicka, S Weitman, et al.
Cellular Immunology|November 1, 1987
Characterization of the fine specificity and antigen markers associated with the receptor of autoreactive T-cell hybridomasR S Quartin, M Monestier, T M Moran, et al.
Anticancer Research|August 11, 2001
Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cellsW Wang, S J Waters, J R MacDonald, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
The Journal of Experimental Medicine|January 1, 1984
Antigen recognition by a T cell clone outside the context of the major histocompatibility complex. A role for Mls in antigen presentationS J Waters, S D Waksal, G P Norton, et al.
Investigational New Drugs|September 20, 2001
Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulvenA L Woynarowska BAHigdon, R M Muñoz, P Bushong, et al.
The American Review of Respiratory Disease|May 1, 1983
Immunogenetic and clinical findings in idiopathic pulmonary fibrosis. Association with the B-cell alloantigen HLA-DR2D M Libby, A Gibofsky, M Fotino, et al.
Journal of Pharmaceutical Sciences|September 1, 1995
Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparisonP Veng-Pedersen, J A Wilhelm, T B Zakszewski, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1984
Antigen presentation by murine and human cells to a murine T-cell hybridoma: demonstration of a restriction element associated with a major histocompatibility complex class II determinant(s) shared by both speciesS J Waters, R J Winchester, F Nagase, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 1, 1995
Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimationJ A Wilhelm, P Veng-Pedersen, T B Zakszewski, et al.
Anesthesia and Analgesia|August 1, 1986
Oxygen concentrations required for reductive defluorination of halothane by rat hepatic microsomesR C Lind, A J Gandolfi, I G Sipes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2004
Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenograftsE S van Laar, E Izbicka, S Weitman, et al.
Cellular Immunology|November 1, 1987
Characterization of the fine specificity and antigen markers associated with the receptor of autoreactive T-cell hybridomasR S Quartin, M Monestier, T M Moran, et al.
Anticancer Research|August 11, 2001
Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cellsW Wang, S J Waters, J R MacDonald, et al.
Pageof 3